The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)

被引：1
|
作者：
Chowdhury, S. [1 ]
Birtle, A. J. [2 ]
Bjartell, A. [3 ]
Costa, L. [4 ,5 ]
Feyerabend, S. [6 ]
Galli, L. [7 ]
Lumen, N. [8 ]
Kalinka-Warzocha, E. [9 ]
Maroto, P. [10 ]
Matveev, V. B. [11 ]
Paiss, T. [12 ]
Spaeth, D. [13 ]
Klumper, E. [14 ]
Thingstad, T. [15 ]
Wapenaar, R. [16 ]
Lee, E. [17 ]
机构：
[1] Guys Hosp, Dept Urol, London SE1 9RT, England
[2] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
[3] Skane Univ Hosp, Dept Urol, Malmo, Sweden
[4] Hosp Santa Maria, Lisbon, Portugal
[5] Univ Lisbon, Inst Med Mol, P-1699 Lisbon, Portugal
[6] Studienpraxis Urol, Nurtingen, Germany
[7] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy
[8] Ghent Univ Hosp, Dept Urol, Ghent, Belgium
[9] Wojewodzki Szpital Specjalistyczny Im M Kopernika, Lodz, Poland
[10] St Pau Hosp, Barcelona, Spain
[11] NN Blokhin Canc Res Ctr, Dept Oncourol, Moscow, Russia
[12] Urol Team Ulm, Ulm, Germany
[13] Ctr Oncol Gentilly, Nancy, France
[14] SMS Oncol BV, Amsterdam, Netherlands
[15] Janssen Cilag AS, Oslo, Norway
[16] Janssen Cilag BV, Tilburg, Netherlands
[17] Janssen Pharmaceut, EMEA Med Affairs, B-2340 Beerse, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31367-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2548
引用
收藏
页码：S492 / S492
页数：1
相关论文
共 50 条
  • [41] A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    CANCER RESEARCH, 2012, 72
  • [42] Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Angelergues, Antoine
    Mercier, Florence
    Flechon, Aude
    Guillot, Aline
    Le Moulec, Sylvestre
    Gravis, Gwenaelle
    Beuzeboc, Philippe
    Massard, Christophe
    Fizazi, Karim
    Rouge, Thibault De La Motte
    Elaidi, Reza-Thierry
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [43] Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
    Lozano, Rebeca
    Castro, Elena
    Piulats, Josep M.
    Medina, Ana
    Villa Guzman, Jose Carlos
    Garcia Carbonero, Iciar
    Villatoro, Rosa
    Angel Arranz, Jose
    Luis Perez-Gracia, Jose
    Garde, Javier
    Gonzalez del Alba, Aranzazu
    Montesa, A.
    Luque, Raquel
    Borrega, Pablo
    Vazquez, Sergio
    Martinez, Esther
    Gonzalez Gragera, Belen
    Romero-Laorden, Nuria
    Olmos, David
    Lorente, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [44] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rodrigues, Daniel Nava
    Mehra, Niven
    Figueiredo, Ines
    Crespo, Mateus
    Riisnaes, Ruth
    Miranda, Susana A. A.
    Ferreira, Ana
    Tunariu, Nina
    Perez-Lopez, Raquel
    Boysen, Gunther
    Sharp, Adam
    Bianchini, Diletta
    Kolinsky, Michael
    Rescigno, Pasquale
    Zafeiriou, Zafetris
    Mateo, Joaquin
    De Bono, Johann S.
    MODERN PATHOLOGY, 2016, 29 : 251A - 251A
  • [45] Combining molecular and functional imaging in metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Scarpi, Emanuela
    Wetterskog, Daniel
    Caroli, Paola
    Romanel, Alessandro
    Lolli, Cristian
    Jayaram, Anuradha
    Gurioli, Giorgia
    Brighi, Nicole
    Poti, Giulia
    Wingate, Anna
    Schepisi, Giuseppe
    Matteucci, Federica
    Paganelli, Giovanni
    Demichelis, Francesca
    Attard, Gerhardt
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).
    Mak, Blossom
    Mahon, Kate Lynette
    Stockler, Martin R.
    Joshua, Anthony M.
    Zhang, Alison Yan
    Parnis, Francis
    Meikle, Peter
    Horvath, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [47] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Rodrigues, Daniel Nava
    Mehra, Niven
    Figueiredo, Ines
    Crespo, Mateus
    Riisnaes, Ruth
    Miranda, Susana A. A.
    Ferreira, Ana
    Tunariu, Nina
    Perez-Lopez, Raquel
    Boysen, Gunther
    Sharp, Adam
    Bianchini, Diletta
    Kolinsky, Michael
    Rescigno, Pasquale
    Zafeiriou, Zafeiris
    Mateo, Joaquin
    De Bono, Johann S.
    LABORATORY INVESTIGATION, 2016, 96 : 251A - 251A
  • [48] Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC)
    Sonpavde, Guru
    Wang, Christopher G.
    Galsky, Matthew D.
    Oh, William K.
    Armstrong, Andrew J.
    BJU INTERNATIONAL, 2015, 116 (01) : 17 - 29
  • [49] Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
    Higano, C. S.
    Dizdarevic, S.
    Sundar, S.
    Agarwal, N.
    Essler, M.
    Song, D.
    George, S.
    Shore, N. D.
    Kurtinecz, M.
    Verholen, F.
    Sandstrom, P.
    Sartor, O.
    George, D. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S640 - S641
  • [50] INTERMITTENT (RECHALLENGE) CHEMOTHERAPY WITH DOCETAXEL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Bracarda, Sergio
    Rossi, Marta
    Hamzaj, Alketa
    De Angelis, Verena
    De Simone, Valeria
    Caserta, Claudia
    Crino, Lucio
    ANNALS OF ONCOLOGY, 2009, 20
12345